These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

400 related articles for article (PubMed ID: 1903843)

  • 1. [Antibiotic inhalation in cystic fibrosis. A review of the literature].
    Steinkamp G
    Monatsschr Kinderheilkd; 1991 Feb; 139(2):73-80. PubMed ID: 1903843
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Value of inhaled antibiotics in cystic fibrosis patients.
    Wunderlich P; Paul KD; Wehner J
    Acta Univ Carol Med (Praha); 1990; 36(1-4):34-6. PubMed ID: 2130713
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Challenges with current inhaled treatments for chronic Pseudomonas aeruginosa infection in patients with cystic fibrosis.
    Greally P; Whitaker P; Peckham D
    Curr Med Res Opin; 2012 Jun; 28(6):1059-67. PubMed ID: 22401602
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Differences in prevalence and treatment of Pseudomonas aeruginosa in cystic fibrosis centres in Denmark, Norway and Sweden.
    Knudsen PK; Olesen HV; Høiby N; Johannesson M; Karpati F; Laerum BN; Meyer P; Pressler T; Lindblad A;
    J Cyst Fibros; 2009 Mar; 8(2):135-42. PubMed ID: 19157995
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Optimal airway antimicrobial therapy for cystic fibrosis: the role of inhaled aztreonam lysine.
    Elborn JS; Henig NR
    Expert Opin Pharmacother; 2010 Jun; 11(8):1373-85. PubMed ID: 20426707
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Therapeutic approaches to chronic cystic fibrosis respiratory infections with available, emerging aerosolized antibiotics.
    Ballmann M; Smyth A; Geller DE
    Respir Med; 2011 Dec; 105 Suppl 2():S2-8. PubMed ID: 22208546
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Novel inhaled combined antibiotic formulations in the treatment of Pseudomonas aeruginosa airways infections in cystic fibrosis.
    Antoniu S
    Expert Rev Anti Infect Ther; 2015 Jul; 13(7):897-905. PubMed ID: 25921312
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antibiotic use in cystic fibrosis.
    Eisenberg JD
    Curr Opin Pulm Med; 1996 Nov; 2(6):439-46. PubMed ID: 9363182
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Use of inhaled tobramycin in patients with cystic fibrosis].
    Chermenskiĭ AG; Gembitskaia TE
    Ter Arkh; 2010; 82(8):76-8. PubMed ID: 20873251
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Open label study of inhaled aztreonam for Pseudomonas eradication in children with cystic fibrosis: The ALPINE study.
    Tiddens HA; De Boeck K; Clancy JP; Fayon M; H G M A; Bresnik M; Derchak A; Lewis SA; Oermann CM;
    J Cyst Fibros; 2015 Jan; 14(1):111-9. PubMed ID: 25091537
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety and pharmacokinetics of ciprofloxacin dry powder for inhalation in cystic fibrosis: a phase I, randomized, single-dose, dose-escalation study.
    Stass H; Delesen H; Nagelschmitz J; Staab D
    J Aerosol Med Pulm Drug Deliv; 2015 Apr; 28(2):106-15. PubMed ID: 25050456
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Inhaled antibiotic therapy in cystic fibrosis].
    Girón Moreno RM; Salcedo Posadas A; Mar Gómez-Punter R
    Arch Bronconeumol; 2011 Jun; 47 Suppl 6():14-8. PubMed ID: 21703474
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Novel tobramycin inhalation powder in cystic fibrosis subjects: pharmacokinetics and safety.
    Geller DE; Konstan MW; Smith J; Noonberg SB; Conrad C
    Pediatr Pulmonol; 2007 Apr; 42(4):307-13. PubMed ID: 17352404
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Aerosolized antibiotic therapy for chronic cystic fibrosis airway infections: continuous or intermittent?
    Lo D; VanDevanter DR; Flume P; Smyth A
    Respir Med; 2011 Dec; 105 Suppl 2():S9-17. PubMed ID: 22208548
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Aztreonam inhalation solution for suppressive treatment of chronic Pseudomonas aeruginosa lung infection in cystic fibrosis.
    Assael BM
    Expert Rev Anti Infect Ther; 2011 Nov; 9(11):967-73. PubMed ID: 22029514
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evidence for the efficacy of aztreonam for inhalation solution in the management of Pseudomonas aeruginosa in patients with cystic fibrosis.
    Hansen C; Skov M
    Ther Adv Respir Dis; 2015 Feb; 9(1):16-21. PubMed ID: 25471692
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A more objective approach to the evaluation of antimicrobial therapy in cystic fibrosis.
    Valletta EA; Rigo A; Bonazzi L; Zanolla L; Mastella G
    Acta Univ Carol Med (Praha); 1990; 36(1-4):44-5. PubMed ID: 2130717
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Antibiotic treatment strategies in cystic fibrosis].
    Smaczny C
    Pneumologie; 1996 Dec; 50 Suppl 3():831-3. PubMed ID: 9157437
    [No Abstract]   [Full Text] [Related]  

  • 19. [Inhalational antibiotic therapy in patients with cystic fibrosis and Pseudomonas infection].
    Mordasini C; Aebischer CC; Schoch OD
    Schweiz Med Wochenschr; 1997 May; 127(21):905-10. PubMed ID: 9289818
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tobramycin Inhalation Powder™: a novel drug delivery system for treating chronic Pseudomonas aeruginosa infection in cystic fibrosis.
    Parkins MD; Elborn JS
    Expert Rev Respir Med; 2011 Oct; 5(5):609-22. PubMed ID: 21955231
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.